Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GLUE NASDAQ:KALV NASDAQ:SOPH NASDAQ:VIR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGLUEMonte Rosa Therapeutics$18.24+6.7%$18.52$4.12▼$25.77$1.44B1.6910,018 shs1.09 million shsKALVKalVista Pharmaceuticals$27.00$24.16$9.83▼$27.00$1.44B-0.123.07 million shsN/ASOPHSOPHiA GENETICS$4.88-6.2%$4.98$2.59▼$5.70$356.13M0.98102,350 shs94,960 shsVIRVir Biotechnology$8.61+1.1%$9.47$4.16▼$11.66$1.44B1.651.58 million shs1.18 million shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGLUEMonte Rosa Therapeutics+3.51%-1.50%-10.52%+6.74%+238.61%KALVKalVista Pharmaceuticals-0.02%+0.17%+0.99%+59.36%+100.56%SOPHSOPHiA GENETICS-0.38%+4.84%+12.31%+12.80%+73.33%VIRVir Biotechnology+3.27%-6.89%-9.36%-7.99%+62.29%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGLUEMonte Rosa Therapeutics$18.24+6.7%$18.52$4.12▼$25.77$1.44B1.6910,018 shs1.09 million shsKALVKalVista Pharmaceuticals$27.00$24.16$9.83▼$27.00$1.44B-0.123.07 million shsN/ASOPHSOPHiA GENETICS$4.88-6.2%$4.98$2.59▼$5.70$356.13M0.98102,350 shs94,960 shsVIRVir Biotechnology$8.61+1.1%$9.47$4.16▼$11.66$1.44B1.651.58 million shs1.18 million shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGLUEMonte Rosa Therapeutics+3.51%-1.50%-10.52%+6.74%+238.61%KALVKalVista Pharmaceuticals-0.02%+0.17%+0.99%+59.36%+100.56%SOPHSOPHiA GENETICS-0.38%+4.84%+12.31%+12.80%+73.33%VIRVir Biotechnology+3.27%-6.89%-9.36%-7.99%+62.29%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGLUEMonte Rosa Therapeutics 2.67Moderate Buy$32.5078.18% UpsideKALVKalVista Pharmaceuticals 2.22Hold$30.6013.33% UpsideSOPHSOPHiA GENETICS 2.33Hold$7.5053.69% UpsideVIRVir Biotechnology 2.89Moderate Buy$20.88142.45% UpsideCurrent Analyst Ratings BreakdownLatest SOPH, KALV, GLUE, and VIR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/11/2026VIRVir Biotechnology Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$23.00 ➝ $27.006/3/2026VIRVir Biotechnology Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$20.00 ➝ $21.005/11/2026GLUEMonte Rosa Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D-) ➝ Sell (D)5/11/2026GLUEMonte Rosa Therapeutics JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$30.00 ➝ $31.005/8/2026VIRVir Biotechnology Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$23.005/6/2026SOPHSOPHiA GENETICS BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$8.005/1/2026KALVKalVista Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral$37.00 ➝ $27.004/30/2026KALVKalVista Pharmaceuticals JonesTradingSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold4/30/2026KALVKalVista Pharmaceuticals Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold4/29/2026KALVKalVista Pharmaceuticals Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold4/29/2026KALVKalVista Pharmaceuticals Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold(Data available from 6/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGLUEMonte Rosa Therapeutics$123.67M12.46N/AN/A$3.58 per share5.09KALVKalVista Pharmaceuticals$49.08M29.29N/AN/A$2.71 per share9.96SOPHSOPHiA GENETICS$77.27M4.33N/AN/A$0.69 per share7.07VIRVir Biotechnology$68.56M21.18N/AN/A$5.50 per share1.57Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGLUEMonte Rosa Therapeutics-$38.63M-$1.48N/AN/AN/A-302.69%-40.99%-25.94%8/6/2026 (Estimated)KALVKalVista Pharmaceuticals-$109.52M-$3.46N/A36.00N/AN/A-341.44%-111.94%8/13/2026 (Estimated)SOPHSOPHiA GENETICS-$79M-$0.52N/AN/AN/A-44.48%-62.74%-21.85%8/4/2026 (Estimated)VIRVir Biotechnology-$437.99M-$3.13N/AN/AN/A-638.88%-53.31%-41.76%8/5/2026 (Estimated)Latest SOPH, KALV, GLUE, and VIR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026KALVKalVista Pharmaceuticals-$0.3763-$0.43-$0.0538-$0.43$39.03 million$40.86 million5/7/2026Q1 2026GLUEMonte Rosa Therapeutics-$0.3882-$0.45-$0.0618-$0.45$10.95 million$4.21 million5/6/2026Q1 2026VIRVir Biotechnology-$0.01-$0.85-$0.84-$0.85$55.49 million($0.03) million5/5/2026Q1 2026SOPHSOPHiA GENETICS-$0.2325-$0.27-$0.0375-$0.27$20.40 million$21.69 million3/17/2026Q4 2025GLUEMonte Rosa Therapeutics-$0.45-$0.55-$0.10-$0.55$17.09 million$2.78 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthGLUEMonte Rosa TherapeuticsN/AN/AN/AN/AN/AKALVKalVista PharmaceuticalsN/AN/AN/AN/AN/ASOPHSOPHiA GENETICSN/AN/AN/AN/AN/AVIRVir BiotechnologyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGLUEMonte Rosa TherapeuticsN/A9.549.54KALVKalVista Pharmaceuticals8.185.175.10SOPHSOPHiA GENETICS1.052.061.90VIRVir BiotechnologyN/A7.117.11Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGLUEMonte Rosa Therapeutics79.96%KALVKalVista PharmaceuticalsN/ASOPHSOPHiA GENETICS31.59%VIRVir Biotechnology65.32%Insider OwnershipCompanyInsider OwnershipGLUEMonte Rosa Therapeutics6.40%KALVKalVista Pharmaceuticals4.30%SOPHSOPHiA GENETICS4.88%VIRVir Biotechnology2.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGLUEMonte Rosa Therapeutics9084.48 million79.07 millionOptionableKALVKalVista Pharmaceuticals10053.24 million50.95 millionOptionableSOPHSOPHiA GENETICS52068.49 million65.14 millionNot OptionableVIRVir Biotechnology580168.65 million163.76 millionOptionableSOPH, KALV, GLUE, and VIR HeadlinesRecent News About These CompaniesMorgan Stanley Raises Vir Biotechnology (NASDAQ:VIR) Price Target to $27.00June 11 at 8:46 AM | marketbeat.comVir Biotechnology Adds Timothy Coughlin to Board, Audit ChairJune 10 at 6:10 PM | tipranks.comVir Biotechnology Announces Appointment of Timothy Coughlin to its Board of DirectorsJune 10 at 4:05 PM | businesswire.comWINTON GROUP Ltd Buys 131,555 Shares of Vir Biotechnology, Inc. $VIRJune 10 at 7:23 AM | marketbeat.comBarclays Sticks to Its Buy Rating for Vir Biotechnology (VIR)June 8, 2026 | theglobeandmail.comAnalysts Offer Insights on Healthcare Companies: Cabaletta Bio (CABA) and Vir Biotechnology (VIR)June 8, 2026 | theglobeandmail.comIs Vir Biotechnology, Inc. (VIR) A Good Stock To Buy Now?June 7, 2026 | insidermonkey.comIs Vir Biotechnology, Inc. (VIR) A Good Stock To Buy Now?June 7, 2026 | finance.yahoo.comVir Biotechnology (NASDAQ:VIR) Given New $21.00 Price Target at Leerink PartnersJune 4, 2026 | americanbankingnews.comVir Biotechnology (NASDAQ:VIR) Price Target Raised to $21.00June 3, 2026 | marketbeat.comInsider Selling: Vir Biotechnology (NASDAQ:VIR) Director Sells 3,200 Shares of StockJune 3, 2026 | insidertrades.comVir Biotechnology, Inc. (VIR) Presents at EASL Congress 2026 - SlideshowMay 30, 2026 | seekingalpha.comVir Biotechnology, Inc. (NASDAQ:VIR) Given Consensus Rating of "Moderate Buy" by AnalystsMay 28, 2026 | marketbeat.comSF Biotech Boss Slashes Labs, Bets Big On Cancer In High-Stakes Vir MakeoverMay 27, 2026 | hoodline.comHUBS Group AG Purchases 203,203 Shares of Vir Biotechnology, Inc. $VIRMay 27, 2026 | marketbeat.comHow SOLSTICE Phase 2 HDV Data at Vir Biotechnology (VIR) Has Changed Its Investment StoryMay 25, 2026 | finance.yahoo.comWhy a Biotech Fund Opened a New $6 Million Position in Vir Amid a 99% Stock RallyMay 23, 2026 | aol.comAVir Biotechnology to Present Complete Week 96 Data from Phase 2 SOLSTICE Clinical Trial in Hepatitis Delta at the European Association for the Study of the Liver (EASL ...May 19, 2026 | finance.yahoo.comVir Biotechnology Stock Has Nearly Doubled in a Year. One Major Holder Just Trimmed $17 MillionMay 19, 2026 | finance.yahoo.comVir Biotechnology to Present Complete Week 96 Data from Phase 2 SOLSTICE Clinical Trial in Hepatitis Delta at the European Association for the Study of the Liver (EASL) Congress 2026May 18, 2026 | businesswire.comVir Biotechnology Stock Has Doubled This Past Year. One Fund Just Bought 1.2 Million SharesMay 17, 2026 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSOPH, KALV, GLUE, and VIR Company DescriptionsMonte Rosa Therapeutics NASDAQ:GLUE$18.24 +1.14 (+6.67%) Closing price 04:00 PM EasternExtended Trading$18.93 +0.69 (+3.78%) As of 06:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases. It also develops CDK2 to treat ovarian, uterine, and breast cancers. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.KalVista Pharmaceuticals NASDAQ:KALV$27.00 0.00 (0.00%) As of 06/11/2026KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which is in preclinical trial. In addition, the company is developing an orally disintegrating tablet formulation, including KONFIDENT-KID for pediatric use with HAE; KONFIDENT-S for adolescent and adult patients with type I or type II HAE; and KONFIDENT for a potential oral therapy for HAE attacks. The company is headquartered in Cambridge, Massachusetts.SOPHiA GENETICS NASDAQ:SOPH$4.88 -0.32 (-6.15%) Closing price 04:00 PM EasternExtended Trading$4.89 +0.01 (+0.31%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific. SOPHiA GENETICS SA was incorporated in 2011 and is headquartered in Rolle, Switzerland.Vir Biotechnology NASDAQ:VIR$8.61 +0.09 (+1.06%) Closing price 04:00 PM EasternExtended Trading$8.58 -0.03 (-0.33%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SpaceX Rings the Bell and Shatters Every Record Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story? ERock IPO: A $1.3B Power Play Solution Boeing’s Unseen Rebound: Why the Headlines Are Wrong Why Oracle's 10% Drop May Be Telling the Wrong Story Spotify's "North Star" Outlook Was Music to Investors Ears DraftKings Hits the Jackpot With Super App Pivot Cracker Barrel Surges 23% as Earnings Beat Signals Turnaround Progress Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
